CSRWire - Teva Becomes First Pharmaceutical Company to Execute Sustainability-Linked Bond Tied to Both Climate and Access to Medicine Targets
Teva eases debt burden with $400M tender offer as turnaround effort escalates | Fierce Pharma
Teva Bonds: 8.8% Yield To Maturity Understates Upside | Nasdaq
Teva's Credit Rating Cut to Junk by Fitch - Bloomberg
Teva Receives A- Rating from Fitch Ratings with a Stable Outlook Jerusalem, Israel, December 13, 2012 - Teva Pharmaceutical Indu
Tear Sheet: Teva Pharmaceuticals Faces Pressure From Competing Generics, Seeks to Delever Quickly After Actavis Acquisition - Reorg
Teva woes deepen as Fitch cuts credit rating to junk | The Times of Israel
S&P cuts Teva's rating on rising litigation risks
Teva Pharmaceutical (TEVA)
Teva Nailed With S&P Downgrade - TheStreet
Teva Announces $3,500,000,000 Debt Tender Offers for Notes Due 2022-2024 | Business Wire
Teva's Bonds Rally on News of $4.35bn US Opioid Crisis Settlement
Credit Rating Process | A Complete Beginner's Guide
Teva Announces New Environmental, Social and Governance (ESG) Strategy and Goals in 2020 Report | Business Wire
Short interest in Teva Pharmaceutical Industries Limited (NYSE:TEVA) has decreased significantly. - Best Stocks
Moody's Downgrades Teva Bond Rating to “Junk” | Ctech
Idea of the Week: Teva Pharmaceutical—The Top Leader in Generic Drugs | Bondsupermart
S&P Downgrades Teva, Pushing Credit Rating Further Into Junk Territory - Business - Haaretz.com
Teva Pharmaceutical Stock: Prepare For Takeoff (NYSE:TEVA) | Seeking Alpha
Moody's upgrades Teva's rating outlook - גלובס
Healthcare companies face pricing pressure, regulatory wild cards in 2018: S&P | S&P Global Market Intelligence
Teva woes deepen as Fitch cuts credit rating to junk | The Times of Israel
